ClinicalTrials.gov
public full text
Public Domain
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dosimetric equivalence of deep learning prostate contours after LDR brachytherapy: pre-declared margins, patient-level acceptance thresholds and the incremental predictive value of DVH indices#1083509
- Ceramide Containing Multivesicular Emulsion Application . . .#860742
- Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients#1032513
- Glyceryl Eicosapentaenoate Based Topic Products as an Irritant-free Cream and Serum for Hydration of Sensitive Skin#993841
- Skin Imaging to Inform Laser Treatments#802000
Record · ID 802727
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive